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Cancer Surveys-Experimental approach to drug
targeting. Vol. 1, No. 3. A.J.S. DAVIES & M.J.
CRUMPTON (Guest Editors). Series Editor, L.M.
FRANKS, Oxford University Press. 563 pp, 1982,
£12.00. ISSN 0261-2429.
This, the third in the Cancer Surveys series,
maintains the high standard set by the previous
issues. This book covers Experimental Approaches
to Drug Targeting in a manner suitable both for
those already involved in cancer chemotherapy and
attempts to direct anti-cancer agents to the tumour
site, and those with little prior knowledge but who
wish to learn more about the field. It consists of an
authoritative introduction by the Editors and ten
review chapters by different groups actively
involved in drug targeting, followed by a brief
concluding commentary by Prof. G. Westbury.
Most of the chapters are concerned with the use of
monoclonal antibodies for targeting cytotoxic
agents, which is quite reasonable considering the
enormous interest that monoclonal antibodies have
generated in this regard in recent times. The
cytotoxic agents discussed are in most cases toxins
of plant orgin (or their A chain sub-units) which
are candidates as anti-tumour agents if they can be
adequately directed, although some authors
(notably R. Arnon and M. Sela) also point out the
potential of antibodies for targeting conventional
cytotoxic drugs. Perhaps the most important point
about this book is that as well as outlining the
potential for success and various ways of exploiting
tumour-directed agents, it emphasizes the pitfalls
and problems which could occur in theory and
occur in practice. As a result we are given an
optimistic, but realistic, overview of current
progress and future prospects. The rapid publishing
time of the Cancer Surveys series has ensured that
the references and factual information are up to
date. In summary the book can be recommended to
those interested in drug-targeting or cancer
chemotherapy in general, and it offers excellent
value for money. It also serves to whet the appetite
for subsequent issues of Cancer Surveys on other
topics.
M.J. Embleton
CRC Laboratories,
University Park,
Nottingham.
Monoclonal Antibodies in Clinical Medicine. A.
MCMICHAEL & J. FABRE (Editors), Academic Press
Inc. (London) Ltd. 663 pp, 1982, £34.00. ISBN 0
12 485580 6.
This book is exceptional on several counts. First
the breadth of coverage of what will continue to be
for many years a burgeoning field; second, the high
quality of virtually all the contributions and third,
the editing, particularly in respect of individual
chapter cross-referencing, the judiciousness of
including a separate section on 'Practical Aspects',
two detailed appendices with references on the
monoclonal antibodies discussed in the fulsome text
and an extensive bibliography-so often missing
from texts of lesser quality.
The book is concerned with applications of
monoclonal antibodies in clinical medicine as a
whole and there are excellent chapters on their
impact in the fields of Haematology (delineation of
platelet function, characterisation of blood group
antigens), Microbiology (characterisation of
influenzal and Epstein-Barr virus antigens; uses in
Bacteriology and Parasitology, particularly
Malaria), and Neurology (differentiation antigens
of the CNS; antibodies to neurotransmitters).
Oncologists-experimental and clinical-are also
well served, not only in the section specifically
concerned with their discipline, but in others also,
such as in the Genetics section in which McMichael
discusses new approaches to the study of the
structure, genetics and function of HLA antigens
and Goodfellow and Solomon, monoclonal
antibodies and human gene mapping by somatic
cell genetics. This desirable overspill also extends to
descriptions of monoclonal antibodies in the drug
field and to immunohistological applications which,
appearing under "Practical Aspects", is not only
well-illustrated but also, as one might have
anticipated, contains much good advice on
technical matters.
The "Cancer" section is subdivided into 3
chapters. In the first E.S. Lennox discusses the
characterisation of human tumour antigens and
emphasises among other points, the inherent
difficulties in defining "tumour-specific" antigens.
Nevertheless, the ability of tumours to make
products inappropriate to their normal state of
differentiation or to magnify by clonal
amplification, the expression of differentiation
A'> The Macmillan Press Ltd., 1983